Compare Hims and Hers Health Inc (HIMS) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Ryanair Holdings plc — how do they compare? Hims and Hers Health Inc trades at $28.46 (market cap $6.55B), while Ryanair Holdings plc trades at $53.8 (market cap $27.11B). The key difference: Ryanair Holdings plc is far larger — about 4.1× Hims and Hers Health Inc's market cap, and Ryanair Holdings plc pays a 1.66% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Ryanair Holdings plc for 72 Days on average.
| HIMS | RYAAY | |
|---|---|---|
Market Cap | $6.55B | $27.11B |
Volume | 14,842,814 | 2,427,380 |
Sector | Health | Industrials |
52-Week High | $62.76 | $73.82 |
52-Week Low | $14.52 | $51.95 |
Typical Hold Time | 21 Days | 72 Days |
Enterprise Value | $7.25B | $24.18B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.
The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.
RYAAY trades at $56.00, up 0.24% on the day, with a bearish technical signal despite strong fundamentals. The company reported $13.95B revenue and $1.61B net income for 2025, with valuation ratios appearing attractive (P/E 13.43, EV/EBITDA 6.05). Recent news highlights CEO commentary on Boeing MAX 10 delays and fuel cost concerns, while analyst consensus remains positive with 65% buy ratings.
RYAAY presents a value opportunity with solid profitability metrics (ROE 22.41%, net margin 12.13%) but faces near-term headwinds from oil price volatility and operational challenges. The stock's current bearish technical positioning contrasts with fundamental strength, creating potential for recovery if fuel costs stabilize and traffic targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
